ATE275399T1 - Verfahren zur modulierung der t-zell-antwort durch manipulation der transduktion der intrazellulären signale - Google Patents

Verfahren zur modulierung der t-zell-antwort durch manipulation der transduktion der intrazellulären signale

Info

Publication number: ATE275399T1
Authority: AT; Austria
Prior art keywords: cell; methods; response; modulating; kinase
Prior art date: 1994-04-29

Application number

AT95917184T

Other languages

English (en)

Inventor

Carl H June

Original Assignee

Us Navy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-29

Filing date

1995-05-01

Publication date

2004-09-15

1995-05-01 Application filed by Us Navy filed Critical Us Navy

2004-09-15 Application granted granted Critical

2004-09-15 Publication of ATE275399T1 publication Critical patent/ATE275399T1/de

Links

238000000034 method Methods 0.000 title abstract 7
230000005867 T cell response Effects 0.000 title abstract 5
230000003834 intracellular effect Effects 0.000 title abstract 3
230000026683 transduction Effects 0.000 title 1
238000010361 transduction Methods 0.000 title 1
108091007960 PI3Ks Proteins 0.000 abstract 3
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
210000001744 T-lymphocyte Anatomy 0.000 abstract 3
239000003112 inhibitor Substances 0.000 abstract 3
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract 2
239000012190 activator Substances 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract 1
230000020385 T cell costimulation Effects 0.000 abstract 1
230000006023 anti-tumor response Effects 0.000 abstract 1
238000010322 bone marrow transplantation Methods 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000004940 costimulation Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
230000001717 pathogenic effect Effects 0.000 abstract 1
230000026731 phosphorylation Effects 0.000 abstract 1
238000006366 phosphorylation reaction Methods 0.000 abstract 1
108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229960001285 quercetin Drugs 0.000 abstract 1
235000005875 quercetin Nutrition 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
238000007423 screening assay Methods 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 abstract 1
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

AT95917184T 1994-04-29 1995-05-01 Verfahren zur modulierung der t-zell-antwort durch manipulation der transduktion der intrazellulären signale ATE275399T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/245,282 US6632789B1 (en)	1994-04-29	1994-04-29	Methods for modulating T cell responses by manipulating intracellular signal transduction
PCT/US1995/005213 WO1995029673A1 (en)	1994-04-29	1995-05-01	Methods for modulating t cell responses by manipulating intracellular signal transduction

Publications (1)

Publication Number	Publication Date
ATE275399T1 true ATE275399T1 (de)	2004-09-15

Family

ID=22926047

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95917184T ATE275399T1 (de)	1994-04-29	1995-05-01	Verfahren zur modulierung der t-zell-antwort durch manipulation der transduktion der intrazellulären signale

Country Status (8)

Country	Link
US (2)	US6632789B1 (de)
EP (1)	EP0758232B1 (de)
JP (3)	JPH09512553A (de)
AT (1)	ATE275399T1 (de)
AU (1)	AU706761C (de)
CA (1)	CA2189055C (de)
DE (1)	DE69533475T2 (de)
WO (1)	WO1995029673A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6632789B1 (en) *	1994-04-29	2003-10-14	The United States Of America As Represented By The Secretary Of The Navy	Methods for modulating T cell responses by manipulating intracellular signal transduction
US6221841B1 (en) *	1996-10-07	2001-04-24	University Of Massachusetts Medical Center	General receptors for phosphoinositides and uses related thereto
US7670767B1 (en) *	1997-01-16	2010-03-02	The Regents Of The University Of California	Genetic alterations associated with cancer
IT1307787B1 (it) *	1999-07-26	2001-11-19	Univ Firenze	Processo per incrementare la motilita' degli spermatozoi e spermatozoia motilita' superiore cosi' ottenuti.
IL150571A0 (en) *	2000-01-03	2003-02-12	Tr Associates L L C	Novel chimeric proteins and methods for using the same
US6777439B2 (en) *	2000-05-30	2004-08-17	Advanced Research & Technology Institute, Inc.	Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
CA2454976C (en) *	2001-07-26	2011-05-10	Santen Pharmaceutical Co., Ltd.	Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
GB0119865D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119863D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
US7049313B2 (en)	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
KR100504503B1 (ko) *	2003-01-14	2005-08-01	엘지전자 주식회사	공기조화시스템
US7429596B2 (en) *	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
AU2004265149A1 (en)	2003-08-13	2005-02-24	Kudos Pharmaceuticals Limited	Aminopyrones and their use as ATM inhibitors
BRPI0515498A (pt)	2004-09-20	2008-07-29	Kudos Pharm Ltd	inibidores de dna-pk
EP1831225A2 (de)	2004-11-19	2007-09-12	The Regents of the University of California	Entzündungshemmende pyrazolopyrimidine
JP2008521814A (ja) *	2004-11-24	2008-06-26	シェーリングコーポレイション	Ｄａｐ−１０およびその使用
EP1848712A1 (de)	2005-02-09	2007-10-31	Kudos Pharmaceuticals Ltd	Atm-inhibitoren
AR053358A1 (es)	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
WO2007114926A2 (en)	2006-04-04	2007-10-11	The Regents Of The University Of California	Kinase antagonists
EP2094837B1 (de)	2006-12-14	2012-04-25	Medical Research Council	Verwendung von pi3k-, m-tor- und akt-inhibitoren zur induktion der foxp3-expression und zur erzeugung regulatorischer t-zellen
GB2467670B (en) *	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
MX2010007419A (es) *	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (de)	2008-03-14	2018-06-27	Intellikine, LLC	Kinasehemmer und verwendungsverfahren
EP2277881A4 (de)	2008-04-18	2011-09-07	Shionogi & Co	Heterocyclische verbindung mit inhibierender wirkung auf p13k
US20110224223A1 (en) *	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt)	2008-07-08	2018-06-12	Intellikine Inc	compostos inibidores de quinase e métodos de uso
CA2738429C (en)	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
EP2358720B1 (de)	2008-10-16	2016-03-02	The Regents of The University of California	Heteroarylkinasehemmer mit kondensierten ringen
US8476431B2 (en) *	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
CA2799579A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
AU2011309689B2 (en)	2010-09-28	2015-01-15	Hadasit Medical Research Services & Development Ltd.	Compositions and methods for treatment of hematological malignancies
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
ES2637113T3 (es)	2011-01-10	2017-10-10	Infinity Pharmaceuticals, Inc.	Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en)	2011-02-23	2016-03-29	Intellikine Llc	Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
AR088218A1 (es)	2011-07-19	2014-05-21	Infinity Pharmaceuticals Inc	Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es)	2011-08-29	2014-07-09	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
CA2846496C (en)	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja)	2012-09-26	2015-11-09	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｉｒｅ１の調節
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PT3052485T (pt)	2013-10-04	2021-10-22	Infinity Pharmaceuticals Inc	Compostos heterocíclicos e suas utilizações
MX382033B (es)	2014-03-19	2025-03-13	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
SI3151672T1 (sl) *	2014-06-06	2021-03-31	Bluebird Bio, Inc.	Izboljšani T-celični sestavki
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
SG11201811237WA (en)	2016-06-24	2019-01-30	Infinity Pharmaceuticals Inc	Combination therapies
RU2020108454A (ru)	2017-07-31	2021-09-02	Дзе Трастиз Оф Коламбия Юниверсити Ин Дзе Сити Оф Нью Йорк	Соединения, композиции и способы лечения t-клеточного острого лимфобластного лейкоза
EP3809983B1 (de)	2018-06-22	2025-08-27	Mayo Foundation for Medical Education and Research	Verfahren und materialien zur verbesserung der reifung von arteriovenösen fisteln und zur aufrechterhaltung der funktionalität von arteriovenösen fisteln
WO2020010259A1 (en) *	2018-07-06	2020-01-09	Mayo Foundation For Medical Education And Research	Methods and materials for improving transplant outcomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2003455C (en)	1988-11-23	2000-02-22	Craig B. Thompson	Immunotherapy involving cd28 stimulation
EP1488805A2 (de) *	1992-04-07	2004-12-22	The Regents of the University of Michigan	CD28 Immunregulationsweg
US5504103A (en) *	1993-08-25	1996-04-02	Eli Lilly And Company	Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5525503A (en) *	1993-09-28	1996-06-11	Dana-Farber Cancer Institute, Inc.	Signal transduction via CD28
US6632789B1 (en) *	1994-04-29	2003-10-14	The United States Of America As Represented By The Secretary Of The Navy	Methods for modulating T cell responses by manipulating intracellular signal transduction

1994
- 1994-04-29 US US08/245,282 patent/US6632789B1/en not_active Expired - Lifetime
1995
- 1995-05-01 AU AU23982/95A patent/AU706761C/en not_active Expired
- 1995-05-01 AT AT95917184T patent/ATE275399T1/de not_active IP Right Cessation
- 1995-05-01 JP JP7528376A patent/JPH09512553A/ja active Pending
- 1995-05-01 CA CA2189055A patent/CA2189055C/en not_active Expired - Lifetime
- 1995-05-01 DE DE69533475T patent/DE69533475T2/de not_active Expired - Lifetime
- 1995-05-01 WO PCT/US1995/005213 patent/WO1995029673A1/en not_active Ceased
- 1995-05-01 EP EP95917184A patent/EP0758232B1/de not_active Expired - Lifetime
2003
- 2003-10-08 US US10/681,627 patent/US20040072766A1/en not_active Abandoned
2006
- 2006-11-22 JP JP2006315500A patent/JP2007056038A/ja active Pending
2010
- 2010-06-22 JP JP2010141945A patent/JP2010260868A/ja active Pending

Also Published As

Publication number	Publication date
JPH09512553A (ja)	1997-12-16
US20040072766A1 (en)	2004-04-15
CA2189055C (en)	2011-01-18
EP0758232B1 (de)	2004-09-08
WO1995029673A1 (en)	1995-11-09
DE69533475T2 (de)	2005-09-22
DE69533475D1 (de)	2004-10-14
HK1014672A1 (en)	1999-09-30
JP2010260868A (ja)	2010-11-18
AU2398295A (en)	1995-11-29
EP0758232A1 (de)	1997-02-19
JP2007056038A (ja)	2007-03-08
US6632789B1 (en)	2003-10-14
AU706761C (en)	2004-02-19
CA2189055A1 (en)	1995-11-09
AU706761B2 (en)	1999-06-24

Legal Events

Date	Code	Title	Description
2005-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69533475D1 (de)	2004-10-14	Verfahren zur modulierung der t-zell-antwort durch manipulation der transduktion der intrazellulären signale
Zachary et al.	1993	Bombesin, vasopressin, and endothelin rapidly stimulate tyrosine phosphorylation of the focal adhesion-associated protein paxillin in Swiss 3T3 cells.
He et al.	2014	Thiomyristoyl peptides as cell-permeable Sirt6 inhibitors
Lohberger et al.	2019	Mechanical exposure and diacerein treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes
ATE191513T1 (de)	2000-04-15	Verfahren zur amplifikation von nukleinsäuren
BR0007532A (pt)	2001-11-20	Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
BR0210839A (pt)	2004-07-13	Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
DE50212935D1 (de)	2008-12-04	Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
ATE197766T1 (de)	2000-12-15	VERFAHREN ZUR MODULATION VON ßT-ZELL-ANERGYß
ATE308045T1 (de)	2005-11-15	Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
ATE292801T1 (de)	2005-04-15	Verfahren zum screening von inhibitoren von asp2
Saijo et al.	1992	Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in Swiss 3T3 cells
Baccarini et al.	1992	IFN-gamma/lipopolysaccharide activation of macrophages is associated with protein kinase C-dependent down-modulation of the colony-stimulating factor-1 receptor
Yoshida et al.	1996	TheBCL6Gene Is Predominantly Expressed in Keratinocytes at Their Terminal Differentiation Stage
BRPI0415202A (pt)	2006-12-05	método de eliciar uma resposta de célula t contra um epìtopo de célula t em um indivìduo mamìfero hospedeiro, ensaio para testar a eficácia de um método de eliciar uma resposta de célula t, e, kit para realizar os mesmos
Eckberg	1988	Intracellular signal transduction and amplification mechanisms in the regulation of oocyte maturation
Andersson et al.	2000	Signalling to translational activation of tumour necrosis factor-α expression in human THP-1 cells
Doyle et al.	1974	The correlation of DNA synthesis and DNA polymerase activity in the developing chick heart
ATE162721T1 (de)	1998-02-15	Neue sonde zur tumordiagnostik oder tumortherapie
Areces et al.	1994	Functional specificity of cytoplasmic and transmembrane tyrosine kinases: identification of 130-and 75-kilodalton substrates of c-fps/fes tyrosine kinase in macrophages
Uzman et al.	1998	The Role of Intracellular Alkalinization in the Establishment of Anterior Neural Fate inXenopus
Walker et al.	2003	Bacterial lipopolysaccharide modulates protein kinase C signalling in Lymnaea stagnalis haemocytes
Edmunds Jr et al.	1992	The role of ions and second messengers in circadian clock function
DE60142984D1 (de)	2010-10-14	Menschliche hodenspezifische serin/threonin-kinase
Eckberg et al.	1996	Regulation of maturation-promoting factor by protein kinase C in Chaetopterus oocytes